Bavarian Nordic's Covid-19 vaccine data has been delayed

Results from the first six months of a phase II trial of the potential booster were slated for end-August, but analysis has taken longer than expected.

Photo: Lukas Barth/Reuters/Ritzau Scanpix

Towards the end of last month, Bavarian Nordic was meant to present six-month data from its new phase II trial of Covid-19 vaccine ABNCov2 – but the timeline has changed, Danish business daily Børsen reports.

The Danish drugmaker was hoping to demonstrate that the candidate works on all coronavirus variants, and that it provides a longer-lasting protection than vaccines already marketed, by for example Moderna and Pfizer, but analysis has slowed down the announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs